The company markets pharmaceutical formulations, critical care injections, and active pharmaceutical ingredients (APIs) to hospitals and distributors in India and international markets. It operates primarily through a contract manufacturing model where third-party facilities produce its branded and generic medical products.
The company operates in a highly fragmented trading and contract manufacturing space with no proprietary manufacturing or unique R&D. Financial metrics contradict any moat claim, as net margins are extremely thin at 0.8% and revenue has declined at a 3.2% CAGR, indicating a lack of pricing power or brand loyalty.
Earnings are largely reinvested into working capital and advances to suppliers rather than high-return assets. The low average ROE of 4.9% suggests that retained capital is not generating meaningful value for shareholders, and the company is currently seeking to raise significant funds through warrants to support basic operations.
The business collapsed as the massive pile of trade receivables and advances to related parties proved uncollectible, leading to a severe liquidity crunch. Management's decision to prioritize preferential warrant issuances over operational efficiency further diluted minority shareholders while the core trading business, already suffering from negative revenue growth, saw its razor-thin margins evaporate under the weight of rising interest costs. The lack of internal controls and the absence of an audit trail eventually masked a terminal decline in capital turnover, leaving the company as a hollow shell of unrecovered loans and stagnant inventory.
RichFakir rates Chandra Bhagat Pharma Ltd's business quality as poor — 26/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Chandra Bhagat Pharma Ltd is trading about 86% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Chandra Bhagat Pharma Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Chandra Bhagat Pharma Ltd's fair value is about ₹30 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →